Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis

Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis

ABSTRACT Background Gastrointestinal (GI) infections, which often result in or stem from intestinal dysbiosis, can affect the efficacy of immune checkpoint inhibitors (ICIs) and increase the risk of adverse effects, such as colitis. In this study, we explored the impact of GI infections before initi...

Full description

Saved in:
Bibliographic Details
Main Authors: Malek Shatila, Kian Abdul‐Baki, Andres Urias Rivera, Kei Takigawa, Irene Jeong‐Ah Lee, Andrew Sullivan, Tanvi Gupta, Linfeng Lu, Raakhi Menon, Ayesha Khan, Hamza Salim, Elliot Baerman, Carolina Colli Cruz, Cristina Natha, Varun Vemulapalli, Garrett Coleman, Krishnavathana Varatharajalu, Christopher Fan, Pablo Okhuysen, Anthony J. Olszanski, Yan Zhou, Hao Chi Zhang, Mehnaz Shafi, Yinghong Wang
Format: Article
Language:English
Published: Wiley 2025-08-01
Series:Cancer Medicine
Subjects:
gastrointestinal infections
gut microbiome
immune checkpoint inhibitors
immune‐mediated colitis
intestinal dysbiosis
risk factors
Online Access:https://doi.org/10.1002/cam4.71123
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.71123

Similar Items